Emily Riser

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Skin in the Game.

L. Kline, D. Spencer, M. Vaphiades, 2021, Survey of ophthalmology.

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis

B. Weinstock-Guttman, G. Buckle, B. Khatri, 2020, Multiple sclerosis journal - experimental, translational and clinical.

Rationale and design of the tele-exercise and multiple sclerosis (TEAMS) study: A comparative effectiveness trial between a clinic- and home-based telerehabilitation intervention for adults with multiple sclerosis (MS) living in the deep south.

J. Rimmer, Dori Pekmezi, T. Mehta, 2018, Contemporary clinical trials.

COVID-19 Modifications for Remote Teleassessment and Teletraining of a Complementary Alternative Medicine Intervention for People With Multiple Sclerosis: Protocol for a Randomized Controlled Trial

J. Rimmer, T. Mehta, Chia-Ying Chiu, 2020, JMIR Research Protocols.

Supporting successful recruitment in a randomized control trial comparing clinic and home-based exercise among adults with multiple sclerosis

J. Rimmer, T. Mehta, Emily Riser, 2022, Research Involvement and Engagement.